Trastuzumab/Pertuzumab

曲妥珠单抗/帕妥珠单抗

Report date: 2026/05/11 20:01:57

Base Information

Drug NameTrastuzumab/Pertuzumab
Drug Alias NamePertuzumab+Trastuzumab帕妥珠单抗/曲妥珠单抗Trastuzumab+Pertuzumab曲妥珠单抗+帕妥珠单抗帕妥珠单抗/曲妥珠单抗/透明质酸酶 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerColorectal NeoplasmsBreast Neoplasms
Global Approved IndicationsMetastatic breast cancerColorectal NeoplasmsBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancer
Original Approved Country/TerritoryUnited States
Original Approved Date2020/06/29
Country/TerritoryUnited StatesEUMainland China +[4] 
CombinationsYes PertuzumabTrastuzumab
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Hanlin (Chengdu) Biotechnology Co LtdShanghai Henlius Biologics Co LtdChugai Pharmaceutical Co Ltd +[8] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerColorectal NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A